Ultomiris®(ravulizumab-cwvz) – New orphan indication
April 28, 2022 - AstraZeneca announced the FDA approval of Ultomiris (ravulizumab-cwvz), for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
Download PDF
